---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-026938"
form_type: "8-K"
ticker: "TLPH"
cik: "0001427925"
company_name: "TALPHERA, INC."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:02:29.535229+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Talphera Q2 net loss $3.5M ($0.10/sh); NEPHRO study enrollment accelerates

## Summary
- 15 patients enrolled in NEPHRO registrational study; on track for completion by end of 2025, PMA submission Q1 2026.
- Cash and equivalents $6.8M at June 30, 2025; closed $4.9M first tranche of $14.8M financing.
- Net loss from continuing ops $3.5M vs $3.8M YoY; combined R&D/SG&A expenses $3.7M vs $4.3M.
- Reduced 2025 cash operating expense guidance to $16M-$17M from prior $17M-$19M.

## SEC filing metadata
- accession: 0001437749-25-026938
- form_type: 8-K
- ticker: TLPH
- cik: 0001427925
- company_name: TALPHERA, INC.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1427925/000143774925026938/0001437749-25-026938-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1427925/000143774925026938/acrx20250813_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-026938
- JSON: https://secwatch.observer/filing/0001437749-25-026938.json
- Plain text: https://secwatch.observer/filing/0001437749-25-026938.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.